Daily statin therapy reduces the risk of heart attack and stroke in people aged over 70, according to the first large randomised trial focused on otherwise healthy older adults. The study, led by Australian researchers, also reported a low incidence of serious side‑effects in the trial population.
What the trial did and found
Researchers enrolled almost 10,000 participants aged over 70 and randomised them to receive either a daily statin or a placebo. Recruitment involved nearly 3,400 general practitioners across Australia. The trial specifically excluded people who had previously experienced a major heart event — such as a heart attack, stroke, or heart surgery — in order to assess whether statins prevent first occurrences of these outcomes in older adults who are otherwise healthy.
The results showed that statin therapy reduced the risk of major cardiovascular events, including heart attacks and strokes, among the study population, while serious adverse effects were uncommon.
Why this matters
Guidance on statin use has historically focused on middle‑aged adults or on people of any age who have already had a cardiovascular event. Doctors previously lacked robust evidence about whether prescribing statins as primary prevention for people aged 70 and over is safe and effective. As populations age, the absolute burden of heart disease shifts towards older groups, making this question increasingly important.
As one of the study's co‑authors noted, the risk that drives most major cardiovascular events:
“is increasing age”.
The trial therefore addresses an important gap in the evidence base, providing clinicians and policymakers with data to weigh the potential benefits and harms of starting statins in later life.
Implications for practice and policy
While the study suggests a net benefit in reducing first heart attacks and strokes in older adults, several practical questions remain. Clinicians will need to consider:
- individual patient life expectancy and comorbidities;
- concurrent medications and the potential for drug interactions;
- patient preferences about preventive treatments and tolerability.
Health services and guideline committees may now review recommendations for primary prevention with statins in older age groups. Any change in national prescribing guidance would have wide ramifications for general practice workloads and drug‑funding decisions.
Study strengths and limitations
The trial's strengths include its randomised design, large sample size and broad recruitment through thousands of GPs, enhancing generalisability to real‑world primary care. However, the published summary does not detail the length of follow‑up, the specific magnitude of risk reduction, or subgroup analyses by age bands, sex, frailty or other conditions — information clinicians will want when applying findings to individual patients.
| Key trial figures | Value |
|---|---|
| Participants | Almost 10,000 |
| GPs involved | Nearly 3,400 |
| Population | Adults aged over 70 without prior major cardiovascular events |
Further details on absolute risk reduction, number needed to treat, and safety endpoints will be essential to determine how broadly to apply the findings. The study authors emphasised the need for evidence in older adults because public health efforts had historically focused on preventing premature cardiovascular death in middle age.
For clinicians, patients and policymakers, this trial provides an important piece of the evidence puzzle. It does not automatically mean all people aged over 70 should be started on statins, but it strengthens the case for shared decision‑making informed by the new trial data.
Health services will now be watching for full publication of the trial's results and for guidance from national bodies on how to interpret and implement the findings in routine care.
